In a blog post over the summer, the U.S. FDA announced its
plans for minimizing the impact of the Zika virus by partnering
with other U.S. government agencies, the private sector
and the international regulatory community, including the
WHO and ANVISA (the Brazilian Health Regulatory Agency)
on vaccines and treatments. As of July, 120 FDA staff members
are working in response to the outbreak.